

Technical Report No. 47  
Preparation of Virus  
Spikes Used for Virus  
Clearance Studies



2010

# **Preparation of Virus Spikes Used for Virus Clearance Studies Task Force**

---

## **Authors**

**Damon Asher**, PhD, Millipore Corp.  
**Kurt Brorson**, PhD, U.S. Food and Drug Administration  
**JoAnn Hotta**, Talecris Biotherapeutics  
**Joseph Hughes**, PhD, WuXi AppTec, Inc.  
**Jerold Martin**, Pall Life Sciences  
**Horst Ruppach**, NewLab BioQuality GmbH  
**Gail Sofer**, SofeWare Associates  
**Martin Wisner**, PhD, BioReliance, Inc.  
**Hannelore Willkommen**, PhD, RBS-Consulting  
**Bin Yang**, PhD, Genentech, Inc.

## **Contributors**

|  |  |
|--|--|
| <b>Mark Bailey</b> , Eli Lilly and Company                           | <b>Mohammed Haque</b> , Pall Life Sciences                   |
| <b>Kate Bergman</b> , Lancaster Labs.                                | <b>Arifa Khan</b> , PhD, U.S. Food and Drug Administration   |
| <b>Johannes Blümel</b> , PhD, Paul-Ehrlich Institut                  | <b>Richard Levy</b> , PhD, PDA                               |
| <b>Jeri Anne Boose</b> , Compliance Insight, Inc.                    | <b>Scott Lute</b> , U.S. Food and Drug Administration        |
| <b>Mark Cabatingan</b> , Hoffmann- La Roche Inc.                     | <b>Carol Marcus-Sekura</b> , BASI                            |
| <b>Dayue Chen</b> , PhD, Eli Lilly and Company                       | <b>Michael Morgan</b> , Asashi Kasei, Planova Division       |
| <b>Qi Chen</b> , PhD, Genentech, Inc.                                | <b>Masahiro Oda</b> , Pall Life Sciences                     |
| <b>Michael Colman</b> , Millipore Corp.                              | <b>Leonard Pease</b> , PhD, University of Utah               |
| <b>Michelle Davis</b> , Talecris Biotherapeutics                     | <b>Kathy Remington</b> , PhD, Catalent Pharma Solutions, Inc |
| <b>Frank van Engelenburg</b> , Kinesis Pharma                        | <b>Barry Rosenblatt</b> , Charles River Labs.                |
| <b>Charles Felice</b> , Centocor Ortho Biotech (Johnson and Johnson) | <b>Michael Ruffing</b> , PhD, Boehringer Ingelheim           |
| <b>Ren-yo Forng</b> , PhD, MedImmune, Inc.                           | <b>Fokke Terpstra</b> , Sanquin NL                           |
| <b>Albrecht Gröner</b> , CSL Behring GmbH                            | <b>Ruth Wolff</b> , Biologics Consulting Group               |

The content and views expressed in this Technical Report are the result of a consensus achieved by the Task Force and are not necessarily views of the organizations they represent or regulatory authorities in the E.U. or the U.S. Government.

# Preparation of Virus Spikes Used for Virus Clearance Studies

**Technical Report No. 47**

ISBN: 978-0-939459-27-8

© 2010 Parenteral Drug Association, Inc.

All rights reserved.





# Table of Contents

|  |           |   |           |
|--|-----------|---|-----------|
| <b>1.0 INTRODUCTION</b> .....                          | 4         | 4.2.2.3 Spectrophotometric Measurement.....               | 25        |
| <b>2.0 GLOSSARY OF TERMS</b> .....                     | 6         | 4.2.2.4 Infectivity to Particle Ratio.....                | 25        |
| <b>3.0 PREPARATION OF VIRUS STOCKS</b> .....           | 10        | 4.2.3 Aggregation.....                                    | 26        |
| 3.1 Introduction.....                                  | 10        | 4.2.3.1 Dynamic Light Scattering (DLS).....               | 26        |
| 3.2 Sourcing of Viruses and Preparation of Virus... 10 |           | 4.2.3.2 Filter Sizing.....                                | 26        |
| 3.2.1 Viruses Used for Viral Clearance Studies .. 10   |           | 4.2.3.3 Newer Methods .....                               | 26        |
| 3.3 Sourcing and Traceability of Viruses..... 12       |           | 4.3 Purity.....   | 26        |
| 3.3.1 Traceability of Viruses..... 12                  |           | 4.3.1 Protein Content.....                                | 26        |
| 3.4 Preparation of Virus Seed .....                    | 13        | 4.3.2 DNA/RNA Content.....                                | 27        |
| 3.4.1 Approaches for Preparation .....                 | 13        | 4.4 Contamination .....                                   | 28        |
| 3.4.2 Virus Seed Preparation .....                     | 14        | 4.4.1 Sterility/Bioburden.....                            | 28        |
| 3.5 Preparation of Master and Working                  |           | 4.4.2 Mycoplasma.....                                     | 28        |
| Virus Banks .....                                      | 14        | 4.4.3 Adventitious Viruses.....                           | 29        |
| 3.5.1 Preparation of the                               |           | 4.4.3.1 <i>In vitro</i> assays .....                      | 29        |
| Master Virus Bank (MVB).....                           | 15        | 4.4.3.2 Immunoassays .....                                | 29        |
| 3.5.2 Preparation of the                               |           | <b>5.0 IMPACT OF VIRUS SPIKE ON THE SCALED</b>            |           |
| Working Virus Bank (WVB) .....                         | 16        | <b>DOWN MODEL AND ON VIRUS REMOVAL AND</b>                |           |
| 3.6 Preparation of Virus Used for                      |           | <b>INACTIVATION</b> .....                                 | <b>30</b> |
| Virus Clearance Studies.....                           | 16        | 5.1 Introduction.....                                     | 30        |
| 3.6.1 Cytopathic Viruses.....                          | 16        | 5.2 Influence of the Virus Spike on the                   |           |
| 3.6.2 Non-cytopathic Viruses .....                     | 17        | Scaled Down Model .....                                   | 30        |
| 3.7 Storage of Virus Stocks.....                       | 17        | 5.2.1 Chromatography .....                                | 30        |
| 3.8 Purification of Viruses.....                       | 18        | 5.2.2 Filtration .....                                    | 31        |
| 3.8.1 Purification by Ultracentrifugation .....        | 18        | 5.2.2.1 Filtration Case Study #1 .....                    | 31        |
| 3.8.1.1 Pelleting.....                                 | 18        | 5.2.2.2 Filtration Case Study #2 .....                    | 32        |
| 3.8.1.2 Cushions.....                                  | 18        | 5.2.2.3 Filtration Case Study #3 .....                    | 33        |
| 3.8.1.3 Gradient Ultracentrifugation.....              | 19        | 5.2.2.4 Filtration Case Study #4 .....                    | 34        |
| 3.8.2 Purification by Membrane Adsorber .....          | 19        | 5.3 Influence of the Virus Spike on the Log <sub>10</sub> |           |
| 3.8.2.1 Purification of Parvoviruses on a Q            |           | Reduction Value (LRV) .....                               | 35        |
| Membrane Adsorber.....                                 | 19        | 5.3.1 Chromatography .....                                | 36        |
| 3.9 Methods Used to Reduce Aggregates.....             | 20        | 5.3.2 Filtration .....                                    | 36        |
| 3.9.1 Filtration .....                                 | 20        | 5.3.2.1 Filtration Case Study #5 .....                    | 37        |
| 3.9.2 Filtration at the Spiking Step .....             | 21        | 5.3.2.2 Filtration Case Study #6 .....                    | 37        |
| 3.9.3 Sonication .....                                 | 22        | 5.3.2.3 Filtration Case Study #7 .....                    | 39        |
| <b>4.0 METHODS FOR CHARACTERIZATION</b> .....          | <b>23</b> | 5.3.2.4 Filtration Case Study #8 .....                    | 40        |
| 4.1 Identity Testing.....                              | 23        | 5.3.2.5 Filtration Case Study #9 .....                    | 42        |
| 4.1.1 Sequencing.....                                  | 23        | 5.3.2.6 Filtration Case Study #10 .....                   | 42        |
| 4.1.2 Immunological Assays.....                        | 23        | 5.4 Influence of Virus Spike on Inactivation.....         | 43        |
| 4.2 Functional Properties.....                         | 24        | 5.4.1 Inactivation Case Study #1                          |           |
| 4.2.1 Infectivity Assays.....                          | 24        | (Pasteurization).....                                     | 43        |
| 4.2.1.1 Data Analyses and Validation of                |           | 5.4.2 Inactivation Case Study #2                          |           |
| Methods for Virus Enumeration .....                    | 24        | (Extreme pH) .....  | 44        |
| 4.2.2 Total Particle Count.....                        | 24        | 5.4.3 Inactivation Case Study #3                          |           |
| 4.2.2.1 Electron Microscopic Determinations. 24        |           | (Low pH).....   | 44        |
| 4.2.2.2 Quantitative PCR .....                         | 25        | 5.5 Conclusion/Discussion .....                           | 45        |
|  |           | <b>6.0 PHAGE PREPARATIONS</b>                             |           |
|  |           | <b>FOR SPIKING STUDIES</b> .....                          | <b>46</b> |

|   |           |   |           |
|---|-----------|---|-----------|
| 6.1 Typical Use of Phages in Spiking Studies .....                            | 46        | 7.2 Origin, Source, and History of Cells .....                                  | 51        |
| 6.2 Potential Phage Models.....   | 46        | 7.3 Preparation of Cells and Cell Banking .....                                 | 52        |
| 6.2.1 PR772.....  | 47        | 7.3.1 Preparation of Master Cell Bank (MCB)<br>and Working Cell Bank (WCB)..... | 52        |
| 6.2.2 $\Phi$ 6.....   | 48        | 7.3.2 Cultivation and Storage of Cells.....                                     | 53        |
| 6.2.3 $\Phi$ X-174.....   | 48        | 7.3.2.1 Medium Components .....   | 53        |
| 6.2.4 PP7.....  | 48        | 7.3.2.2 Serum.....  | 54        |
| 6.2.5 MS2.....  | 49        | 7.3.2.3 Trypsin.....  | 55        |
| 6.3 Crude vs. CsC1 Banding.....   | 49        | 7.3.3 Cryopreservation and Storage .....  | 55        |
| 6.4 Advantages of Phages over<br>Mammalian Viruses in Filter Studies .....    | 50        | 7.4 Cell Bank Testing .....   | 55        |
| <b>7.0 CONTROL OF CELLS USED FOR VIRUS<br/>PROPAGATION AND TITRATION.....</b> | <b>51</b> | 7.5 Cell Line Characterization .....  | 56        |
| 7.1 Introduction.....   | 51        | 7.6 Raw Material Sourcing and Preparation .....                                 | 58        |
|   |           | 7.7 Documentation .....   | 59        |
|   |           | <b>8.0 REFERENCES.....</b>  | <b>61</b> |

## FIGURES AND TABLES INDEX

|                         |  |    |                         |  |    |
|-------------------------|--|----|-------------------------|--|----|
| <b>Table 3.2.1</b>      | Mammalian Viruses Used in Virus Validation Studies.....  | 11 | <b>Figure 5.3.2.2-2</b> | LRV Of PPV Using PPV Preparations of Different Purity .....  | 39 |
| <b>Figure 3.5</b>       | Master and Working Virus Bank Preparation Flowchart.....   | 15 | <b>Figure 5.3.2.3</b>   | Reduced LRV Observed with Flow Decay in a Small Virus Retentive Filter Caused by High Molecular Weight DNA ..... | 40 |
| <b>Table 3.7</b>        | Stability of SV40 and MMV Stored at -80°C.....   | 18 | <b>Figure 5.3.2.4-1</b> | Purification of X-MuLV and MMV by Sucrose Gradient Centrifugation .....  | 41 |
| <b>Figure 3.8.2.1</b>   | Chromatograph of PPV Purified on a Q Membrane Adsorber .....   | 20 | <b>Figure 5.3.2.4-2</b> | SV40 Stock Purification and Analysis .....   | 41 |
| <b>Table 3.8.2.1</b>    | Purification of PPV on a Q Membrane Adsorber.....  | 20 | <b>Table 5.3.2.4</b>    | SV40 Clearance by a Large Retentive Virus Filter .....   | 42 |
| <b>Table 3.9.2</b>      | Reduction of Virus Titer after Spiking and Pre-Filtration Through 0.2 and 0.1 $\mu$ m Rated Filters..... | 21 | <b>Table 5.3.2.5</b>    | Effect of pH and Spike Quality on Observed LRV of PPV with a Large Virus Filter .....                            | 42 |
| <b>Figure 4.1.2</b>     | Porcine parvovirus Infected Cultures of ST Cells; Uninfected Cells .....                                 | 23 | <b>Table 5.3.2.6</b>    | Removal of Virus Aggregates by Filtration.....   | 43 |
| <b>Table 4.3.1</b>      | Protein Concentration of MMV Purified by Various Means.....  | 27 | <b>Figure 5.4.1</b>     | Inactivation of Different HAV Preparations by Pasteurization in Albumin.....                                     | 43 |
| <b>Table 5.2.1</b>      | Product Yield from Four Scaled-Down Unit Operations Using Different Spike Ratios.....                    | 31 | <b>Figure 5.4.2</b>     | Inactivation of Different HAV Preparations by Extreme pH.....  | 44 |
| <b>Figure 5.2.2.1</b>   | HAV Retention by a Small Size Virus Retentive Filter Using Different Spike Ratios.....                   | 32 | <b>Figure 5.4.5</b>     | Inactivation of Different BVDV Preparations by Low pH.....   | 44 |
| <b>Figure 5.2.2.2</b>   | Capacity of a Virus Filter in Relation to the Purity of the Virus Spike.....                             | 33 | <b>Table 6.2</b>        | Summary of the Properties of Selected Bacteriophages .....   | 47 |
| <b>Figure 5.2.2.3</b>   | Flow Decay in a Small Virus Filter Caused by High Molecular Weight Mammalian DNA .....                   | 34 | <b>Figure 6.3</b>       | Procedure for Growth and Purification of Bacteriophages .....  | 50 |
| <b>Figure 5.2.2.4</b>   | Effect Of Spike Purity on Throughput of Various Small Virus Filters.....                                 | 35 | <b>Figure 7.3.1</b>     | Morphology of Vero Cells in Different Growth Stages.....   | 53 |
| <b>Figure 5.3.1</b>     | Influence of Spike Purity on LRV by a Small Virus Retentive Filter .....                                 | 36 | <b>Figure 7.5-1</b>     | Examples Demonstrating the Susceptibility of Two Cell Lines to Various Viruses .....                             | 57 |
| <b>Figure 5.3.2.1</b>   | Small Virus Filter LRV Observed with Purified and Crude MMV Preparations.....                            | 37 | <b>Figure 7.5-2</b>     | Virus Growth Characteristic (HAV, Strain HM175, in FRHK-4 Cells) .....   | 58 |
| <b>Figure 5.3.2.2-1</b> | Filtration Volume Of Spiked IgG Using Different PPV Preparations ...                                     | 38 | <b>Table 7.7</b>        | Documentation for Cell Banks and the Use of Cells .....  | 60 |

## 1.0 Introduction

Assuring the viral safety of plasma derived biologicals and biopharmaceuticals is critical for safe use by healthcare consumers and successful marketing by industry of these vitally important healthcare products. Incidences of contamination of products derived from human plasma in the past have adversely impacted the health of hundreds of patients and tainted the image of certain segments of the healthcare industry. Today's recombinant biopharmaceuticals have never, as far as we know, presented a similar viral safety issue, and plasma derived products have a better safety record today. This is in large part due to stringent measures taken by the industry and regulators to mitigate viral safety risks.

The current strategy for ensuring viral safety involves multiple levels of control over the product and process, including cell bank screening, source material screening and/or inactivation, and incorporation of specific virus removal or inactivation steps into the production scheme. Validating the ability of the process to remove or inactivate viruses is key in understanding the ability of the manufacturing scheme to clear viruses, in the unlikely event that they do contaminate a process intermediate, and in providing a yard-stick to determine if the clearance capacity is large enough to assure viral safety.

Viral clearance studies start by designing scale-down models of the actual manufacturing unit operations. The objective of the scale-down model is to determine the performance and viral clearance that can be expected of a unit operation at full scale. First, key and critical process parameters, as defined in PDA Technical Report No. 42 (1) or ICH Q8(R2) (2) (e.g., resin contact time, filtration volume per membrane surface), are matched between the scale-down models and commercial large scale processing. Second, key and critical performance parameters, such as step yield and purity, must be representative of the large scale unit operation. Non-key/non-critical operating parameters, like column bed diameter and filter area, are lowered to allow reduction of the model unit operation to a scale practical for lab studies. Other key and critical parameters have to be considered if precipitation steps are investigated and virus is removed by distribution into the precipitate.

Viral clearance studies are conducted by spiking virus into the relevant intermediate and processing the spiked material in a scaled down unit operation. The reduction in the virus load by the unit operation demonstrates the effectiveness of the process step for virus removal or inactivation. The virus spike used in viral clearance studies should be representative of a potential contaminant to the extent achievable. Not only is the selection of appropriate relevant or model viruses important; the properties of the virus spike must also be considered. For example, the presence of serum in a virus spike may be problematic for a validation study of a serum-free manufacturing scheme. As another example, the presence of non-viral extraneous macromolecules, such as proteins and DNA, would be problematic for a validation of a downstream unit operation where the process fluid is presumably a highly purified, non-aggregated protein. It is important that contaminants in the virus spike itself do not impact key or critical performance parameters in a way that makes the scale-down model unrepresentative of the large scale process.

Achievement of these goals involves careful selection and design of virus spikes, both in terms of volume of spiking and purity of the preparations themselves. While it is relatively straightforward to modify the spiking volume to the point where it is non-interfering, achievement of spike purity is more complicated. Presently, some relatively crude spikes are produced directly from unprocessed clarified cell culture lysates or culture supernatants for direct use in validation studies. These spikes, like most biological systems, are relatively heterogeneous and difficult to control. Other virus preparations that are purified by ultracentrifugation/re-suspension, chromatography or other methods possess higher purity, but are still heterogeneous to some degree. The heterogeneities and